News | November 17, 2010

Lunch Symposium to Highlight Medical Simulation Technology

November 17, 2010 – A lunch symposium detailing the evidence for simulation in medical training and other fields will be sponsored by W.L. Gore and Associates at the VEITHsymposium. The EVEResT (European Virtual Reality Endovascular Research Team) lunch symposium will take place Nov. 19 from 12:00 to 1:00 p.m. in the Gramercy A room, second floor.

Companies will demonstrate how new simulation technologies are designed to enhance performance in endovascular procedures.

Rapid advances in technology and a demand for increased patient safety have led to a growing interest in simulation as a training tool for complex procedures. As a result, some of the world’s leading vascular surgeons and radiologists are participating in the event.

It is chaired by Nicholas Cheshire, M.D., professor of vascular surgery, head of circulation sciences and renal medicine, Imperial College Healthcare, Campus St. Mary’s Hospital, London; Mario Lachat, M.D., head of cardiovascular surgery, University Hospital, Zurich, Switzerland; and Isabelle van Herzeele, M.D., Ph.D, consultant at the department of thoracic and vascular surgery at Ghent University Hospital, Belgium and Honorary Fellow at the department of biosurgery and surgical technology NHS Trust, Campus St. Mary's Hospital, London.

The group was founded involving three academic centers and the three specialties (cardiology, radiology, vascular surgery) involved in endovascular treatments of vascular diseases. This collaboration is intended to inspire other academic centers, professional societies and medical device companies to work together and develop a standardized approach for endovascular training and assessment.


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now